FemPulse Corporation announced enrollment of first patients at each of the centers participating in the Company’s EVANESCE-OAB™ (Evaluation of a Non-Implanted Electrical Stimulation Continence Device for Overactive Bladder) U.S. clinical trial. This study will evaluate the treatment of OAB in a home or at-work setting using the Company’s proprietary medical device, the FemPulse System.
